Lercanidipina Falgi (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells. By blocking calcium entry, it prevents muscle contraction, leading to vasodilation of peripheral arteries. This vasodilation reduces systemic vascular resistance, which in turn lowers arterial blood pressure without significantly affecting heart rate or contractility.

The appropriate dose of Lercanidipina Falgi is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it has a lower incidence of cough and may be better tolerated in patients who experience bradycardia. However, individual response varies, and combination therapy is often employed to achieve optimal blood‑pressure control.

Lercanidipina Falgi should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events, although rare, include angioedema, severe hypotension, myocardial infarction, and significant hepatic dysfunction. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain, or unexplained liver‑related symptoms such as jaundice.

Lercanidipina Falgi is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or those who have experienced a recent myocardial infarction unless specifically directed by a cardiologist.